Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting. - Wikidata - awgldk - TriplyDB

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

http://www.wikidata.org/entity/Q37271276

about

Immune-based therapeutics for pediatric cancer.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.

P2860

Q33604121-541C0188-437F-4253-938D-99939FA25D5C Q33752982-B68984B7-C15F-4208-AC1A-4659EFC25952 Q39403785-687E277A-626A-4AC8-9819-5AB5AA8D76B9

P2860

Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

http://www.wikidata.org/entity/Q37271276

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Highlights of the First Intern ...... gress and Challenges" Meeting.

@en

Highlights of the First Intern ...... gress and Challenges" Meeting.

@nl

type

label

Highlights of the First Intern ...... gress and Challenges" Meeting.

@en

Highlights of the First Intern ...... gress and Challenges" Meeting.

@nl

prefLabel

Highlights of the First Intern ...... gress and Challenges" Meeting.

@en

Highlights of the First Intern ...... gress and Challenges" Meeting.

@nl

P1433

Q37271276-68B36F22-357E-4A31-973C-6966443343C0

P1476

Q37271276-2618B949-D810-476B-BEE5-283089AEB224

P2093

Q37271276-0C5B9CF7-3509-4889-A7B8-97C90FD6C5B5

Q37271276-144BE89A-8674-4FC9-AA0C-F3EB3588E81E

Q37271276-85A60EF5-BC67-4B66-A52F-D7018C255449

Q37271276-85A75F37-EF39-4BBC-97F1-E8AA38570CA4

Q37271276-A3D14DF0-E4C7-4D60-9F69-E7B789AF1B6E

P2860

Q37271276-01ACAEC6-323C-4610-BB7F-7C69A15D496E

Q37271276-05401E4D-18AC-48A5-8CB0-73E6A5CAD2D4

Q37271276-0D54B567-8ED4-4525-B308-A99DE0B690C7

Q37271276-0E669A07-4B42-4436-8B4A-47C480A90ED0

Q37271276-1C72F663-5BBA-4FE0-A421-F98F2816583A

Q37271276-2221EE08-D089-4AAF-91DC-FA52394A4110

Q37271276-26655BD3-ACE2-41DA-8EB4-A02F8C679B35

Q37271276-2FF837BA-D1B1-4AE8-B179-E7C7A6D39712

Q37271276-365C4980-7FD2-4919-8312-31C4455D6F9F

Q37271276-3ACACFE3-4406-4159-A9D9-4E1C87E4CFAC

P304

Q37271276-E1C76DC9-2CD7-4979-8E3B-C9D57C12ED4F

P31

Q37271276-2C452B40-C515-4877-A73D-23189ABA32FB

P356

Q37271276-ECE0A93F-6CFB-42AA-8EE1-DCF8A294777E

P433

Q37271276-ACFDDE11-E3D3-4C5D-9EA3-4B1889B2A90C

P478

Q37271276-61C32E3E-1290-440A-AA90-C5CE04105017

P50

Q37271276-9C75B2F4-5CDE-4D5C-B20C-7B7CC25D80A7

Q37271276-A1A5E639-5317-4AFB-898D-6D1A9E77D4A5

P577

Q37271276-258E3965-6F0D-40B8-BCA7-4CC388CB0430

P698

Q37271276-6244D34E-303C-4079-B65A-5175FF9B273C

P921

Q37271276-6E047519-95D4-40BA-9F67-A8EF5B68A19E

P932

Q37271276-5AA0583F-1E92-411E-9576-B1427B13CB4F

P356

MPH.0B013E31819A5D8D

P1433

Journal of Pediatric Hematology/Oncology

P1476

Highlights of the First Intern ...... gress and Challenges" Meeting.

@en

P2093

Crystal L Mackall

http://www.w3.org/2001/XMLSchema#string

Laurence J N Cooper

http://www.w3.org/2001/XMLSchema#string

Paul M Sondel

http://www.w3.org/2001/XMLSchema#string

R Maarten Egeler

http://www.w3.org/2001/XMLSchema#string

Rupert Handgretinger

http://www.w3.org/2001/XMLSchema#string

P2860

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

P304

227-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MPH.0B013E31819A5D8D

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Christian M. Capitini

Franco Locatelli

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19346873

http://www.w3.org/2001/XMLSchema#string

P921

P932

2714285

http://www.w3.org/2001/XMLSchema#string